Patent 7410756 was granted and assigned to Joslin Diabetes Center (company) on August, 2008 by the United States Patent and Trademark Office.
Featured are methods of modulating angiogenesis, e.g., by modulating PKC delta. The methods are useful in the treatment of disorders characterized by aberrant and/or increased blood vessel formation and/or increased permeability. The methods are also useful for treatment a disorder characterized by abnormal, inadequate or unstable blood vessel formation or increased permeability. Also featured are diagnostic and screening methods.